Lack of interaction between citalopram and the CYP3A4 substrate triazolam

Pharmacotherapy

Volumn 20, Issue 7 I, 2000, Pages 750-755

  Nolting, Arno ^a   Abramowitz, Wattanaporn ^a  

^a FOREST RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; CYTOCHROME P450 3A4; TRIAZOLAM;

ADULT; ARTICLE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG METABOLISM; DRUG SAFETY; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; STEADY STATE;

EID: 0033922477     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.20.9.750.35198     Document Type: Article

References (39)

1. Robert P, Montgomery SA. Citalopram in doses of 20-60 mg is effective in depression relapse prevention: a placebo-controlled 6 month study. Int Clin Psychopharmacol 1995;10(suppl 1):29-35.
2. Montgomery SA, Rasmussen JG, Tanghøj P. A 24-week study of 20 mg citalopram, 40 mg citalopram, and placebo in the prevention of relapse of major depression. Int Clin Psychopharmacol 1993;8(3):181-8.
3. Mendels J, Kiev A, Fabre LF. Double-blind comparison of citalopram and placebo in depressed outpatients with melancholia. Depression Anxiety 1999;9(2):54-60.
4. Feighner JP, Overø K. Multicenter, placebo-controlled, fixed dose study of citalopram in moderate to severe depression. J Clin Psychiatry 1999;60(12):824-30.
5. Bougerol T, Scotto JC, Patris M, Strub N, Lemming O, Petersen HEH. Citalopram and fluoxetine in major depression - comparison of two clinical trials in a psychiatrist setting and in general practice. Clin Drug Invest 1997;14(2):77-89.
6. Rosenberg C, Damsbo N, Fuglum E, Jacobsen LV, Horsgard S. Citalopram and imipramine in the treatment of depressive patients in general practice. A Nordic mullicentre clinical study. Int Clin Psychopharmacol 1994;9(suppl):141-8.
7. Shaw DM, Thomas DR, Briscoe MH, et al. A comparison of the antidepressant action of citalopram and amitriptyline. Br J Psychiatry 1986;149:515-17.
8. Baumann P, Larsen F. The pharmacokinetics of citalopram. Rev Contemp Pharmacother 1995;6:287-95.
9. Noble S, Benfield P. Citalopram: a review of its pharmacology, clinical efficacy and tolerability in the treatment of depression. CNS Drugs 1997;8(5):410-31.
10. Sindrup SH, Brøsen K, Hansen MG, Aaes-Jørgensen T, Overø KF, Gram LF. Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Ther Drug Monit 1993;15(1):11-17.
11. von Moltke LL, Greenblatt DJ, Grassi JM, et al. Citalopram and demethylcitalopram in vitro: human cytochromes mediating transformation, and cytochrome inhibitory effects. Biol Psychiatry 1999;46(6):839-49.
12. Greenblatt DJ, von Moltke LL, Harmatz JS, Shader RI. Drug interactions with newer antidepressants: role of human cytochromes P-450. J Clin Psychiatry 1998;59(suppl 15):19-27.
13. Kobayashi K, Chiba K, Yagi T, et al. Identification of cytochrome P-450 isoforms involved in citalopram N-demethylation by human liver microsomes. J Pharmacol Exp Ther 1997;280(2):927-33.
14. Ashton H. Guidelines for the rational use of benzodiazepines. When and what to use. Drugs 1994;48(1):25-40.
15. Garzone PD, Kroboth PD. Pharmacokinetics of the newer benzodiazepines. Clin Pharmacokinet 1989;16(6):337-64.
16. Kronbach T, Mathys D, Umeno M, Gonzalez FJ, Meyer UA. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol 1989;36(1):89-96.
17. von Moltke LL, Greenblatt DJ, Harmatz JS, et al. Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. J Pharmacol Exp Ther 1996;276(2):370-9.
18. Greenblatt DJ. Pharmacology of benzodiazepine hypnotics. J Clin Psychiatry 1992;53(suppl):7-13.
19. Varhe A, Olkkola KT, Neuvonen PJ. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994;56(6 Pt 1):601-7.
20. Wright CE, Lasher-Sisson TA, Steenwyk RC, Swanson CN. A pharmacokinetic evaluation of the combined administration of triazolam and fluoxetine. Pharmacotherapy 1992;12(2):103-6.
21. Senda N, Kohta K, Takahashi T, et al. A highly sensitive method to quantify triazolam and its metabolites with liquid chromatography-mass spectrometry. Biomed Chromatogr 1995;9(1):48-51.
22. Amsterdam JD, Hornig-Rohan M, Maislin G. Efficacy of alprazolam in reducing fluoxetine-induced jitteriness in patients with major depression. J Clin Psychiatry 1994;55(9):394-400.
23. Greenblatt DJ, von Moltke LL, Schmider J, Harmatz JS, Shader RI. Inhibition of human cytochrome P-450-3A isoforms by fluoxetine and norfluoxetine: in vitro and in vivo studies. J Clin Pharmacol 1996;36(9):792-8.
24. von Moltke LL, Greenblatt DJ, Court MH, Duan SX, Harmatz JS, Shader RI. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. J Clin Psychopharmacol 1995;15(2):125-31.
25. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Harmatz JS, Shader RI. Inhibitors of alprazolam metabolism in vitro: effect of serotonin reuptake-inhibitor antidepressants, ketoconazole and quinidine. Br J Clin Pharmacol 1994;38(1): 23-31.
26. von Moltke LL, Greenblatt DJ, Schmider J, et al. Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents. J Clin Pharmacol 1996;36(9):783-91.
27. Greenblatt DJ, Preskorn SH, Cotreau MM, Horst WD, Harmatz JS. Fluoxetine impairs clearance of alprazolam but not of clonazepam. Clin Pharmacol Ther 1992;52(5):479-86.
28. Lasher TA, Fleishaker JC, Steenwyk RC, Antal EJ. Pharmacokinetic pharmacodynamic evaluation of the combined administration of alprazolam and fluoxetine. Psychopharmacology 1991;104(3):323-7.
29. Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF. The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam. Clin Pharmacol Ther 1988;43(4):412-19.
30. Fleishaker JC, Hulst LK. A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine. Eur J Clin Pharmacol 1994;46(1):35-9.
31. Perucca E, Gatti G, Cipolla G, et al. Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in normal volunteers. Clin Pharmacol Ther 1994;56(5):471-6.
32. Richelson E. Pharmacokinetic drug interactions of new antidepressants: a review of the effects on the metabolism of other drugs. Mayo Clin Proc 1997;72(9):835-47.
33. Møller SE, Larsen F, Khan AZ, Rolan PE. Lack of effect of citalopram on the steady state pharmacokinetics of carbamazepine in healthy male subjects. J Clin Psychopharmacol, in press.
34. Grimsley SR, Jann MW, Carter JG, D'Mello AP, D'Souza MJ. Increased carbamazepine plasma concentrations after fluoxetine coadministration. Clin Pharmacol Ther 1991;50(1):10-15.
35. Pearson HJ. Interaction of fluoxetine with carbamazepine [letter, comment]. J Clin Psychiatry 1990;51(3):126.
36. Spina E, Avenoso A, Pollicino AM, Caputi AP, Fazio A, Pisani F. Carbamazepine coadministration with fluoxetine or fluvoxamine. Ther Drug Monit 1993;15(3):247-50.
37. Bergstrom RF, Peyton AL, Lemberger L. Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. Clin Pharmacol Ther 1992;51(3):239-48.
38. Gidal BE, Anderson GD, Seaton TL, Miyoshi HR, Wilenksy AJ. Evaluation of the effect of fluoxetine on the formation of carbamazepine epoxide. Ther Drug Monit 1993;15(5):405-9.
39. Anonymous. Physicians' desk reference. Montvale, NJ: Medical Economics, 2000:3070-3.